Prostatype Genomics AB (publ) (STO:PROGEN)
Sweden · Delayed Price · Currency is SEK 0.7660
+0.0080 (1.06%)
May 4, 2026, 4:58 PM CET
Prostatype Genomics AB Earnings Call Transcripts
Fiscal Year 2025
-
A precision medicine company has launched a prostate cancer genetic test in Europe and the U.S., prioritizing the U.S. due to favorable reimbursement. Awaiting Medicare approval, the firm is expanding its pipeline and sees significant market growth and partnership opportunities.